New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early
New model-based analysis supports TECVAYLI plus DARZALEX FASPRO redefining survival in early-line multiple myeloma.
What changed
New model-based analysis supports TECVAYLI plus DARZALEX FASPRO redefining survival in early-line multiple myeloma.
Why it matters
New model-based analysis supports TECVAYLI plus DARZALEX FASPRO redefining survival in early-line multiple myeloma. — impact context not separately stored; see What changed.
← Dashboard
Sep 23, 2026 03:09 PM ET